試す 金 - 無料
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
Express Pharma
|December 2024
ACG Inspection's Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG Inspection spoke to Viveka Roychowdhury on its USPs, highlighting its modular nature, the zero cost of transition from existing systems, and the advantage of ACG's long term partnerships with global standard setting organisations like GS1 which allow its platforms to deliver regulatory compliance deliverables in advance

ACG Inspection is launching its Life Sciences Cloud in India at the CPHI IndiaPMEC India show, which had its US launch at the Pack Expo US 2024. What has been the response to the US launch in terms of clients who are inquiring from clients or clients who have signed up?
Existing clients who use our products across platforms were excited about ACG's Life Sciences Cloud, as it represents a complete end-to-end solution for their pharmaceutical supply chain needs. Our team has been busy engaging with clients in scenario-based demonstrations and discussing custom solutions to best fit their requirements. The feedback from existing clients has been overwhelmingly positive.
New prospects are, naturally, evaluating it among competing options, comparing modules, and assessing the unique benefits we offer. We welcome their questions and are glad to engage in discussions that help them understand where we differ from others in the industry. After these in-depth discussions, we look forward to formalising partnerships with these new clients.
What's the upfront cost for a new customer or a new client (implementing this solution) versus an existing client? An existing client already has some parts of the solution and this life sciences cloud is the overlying layer which unites everything. Whereas a new customer might have bits and parts from different solution providers. Thus the interoperability between these different moving parts might be a concern. Also, how long does it take to train the staff to adapt to a new technology provider?
このストーリーは、Express Pharma の December 2024 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Express Pharma からのその他のストーリー

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size